FOR INVESTORS
The health technology business is definitely worthy of your attention.
And your investment.
Especially in Nexalin Technology.
FOR INVESTORS
The health technology business is definitely worthy of your attention.
And your investment.
Especially in Nexalin Technology.
THE OPPORTUNITY
The current mental health epidemic in the United States originates with
depression, anxiety, addiction and early dementia.
THE OPPORTUNITY
The current mental health epidemic in the United States originates with depression, anxiety, addiction and early dementia.
Insomnia
Almost 40 million Americans suffer from chronic insomnia (NCBI). Women are up to twice as likely to suffer from insomnia than men.
Anxiety
Anxiety disorders are common, affecting about 18 percent of adults. But only about a third of people with anxiety seek treatment. Anxiety disorders affect an estimated 25 percent of 13- to 18-year-olds. (Anxiety and Depression Association of America).
Depression
Nearly 200,000 people are living with early-onset Alzheimer’s Disease in America alone. That number continues to escalate as it begins to impact some decades before they are to even turn 65. (Mayo Clinic) ***Nexalin is in the process of FDA approval for the treatment of Alzheimer’s.
Addiction
Approximately 20 million Americans battled some form of substance abuse each year, before the additional challenges that Covid19 brought to light. (NSDUH) ***Nexalin is in the process of FDA approval for treatment for addiction.
All of these conditions originate in the health challenges of the brain.
Current treatment of these heath challenges to the brain carry the stigma associated with psychiatrists and the expense associated with psychotherapy. Psychiatrists continue to use the medication model that overwhelms the patient with often unbearable side effects and addiction issues. Psychotherapy is time-consuming and expensive. Both treatment modalities are also associated with social stigmas.
Nexalin technology plans to disrupt and challenge the entire mental health treatment industry.
The NX technology provides a safe and effective treatment that is provided by a medical professional in a clinical setting or in the comfort of the patient’s home.
COMPETITIVE
ADVANTAGE
Nexalin Technology is ideally positioned to be the leader in brain-based health. The basis of this intention lies in the fact that Nexalin does not have a traditional competitor in the marketplace.
- There are several neurostimulators at the high and low end of the market as well as implanted devices and then traditional medications. All have either a high-risk profile or uncomfortable side effects with moderate efficacy.
- With a keen understanding of the market for neurostimulators, Nexalin was intentionally designed as a cost-effective option to all current reimbursed treatments available to the patient.
- Our future proprietary Virtual Clinic program also sets us apart from any existing competitors. (outlined in detail)
COMPETITIVE
ADVANTAGE
Nexalin Technology is ideally positioned to be the leader in brain-based health. The basis of this intention lies in the fact that Nexalin does not have a traditional competitor in the marketplace.
- There are several neurostimulators at the high and low end of the market as well as implanted devices and then traditional medications. All have either a high-risk profile or uncomfortable side effects with moderate efficacy.
- With a keen understanding of the market for neurostimulators, Nexalin was intentionally designed as a cost-effective option to all current reimbursed treatments available to the patient.
- Our future proprietary Virtual Clinic program also sets us apart from any existing competitors. (outlined in detail)
REVENUE
GENERATION
Nexalin Technology is poised to meet its
revenue goals as a result of:
- The rapidly expanding acceptance of telehealth and digital health.
- A newly structured joint venture with an experienced medical technology distribution company in China to design and implement a comprehensive business model and distribution plan for China, Hong Kong, Macau and Taiwan.
- Our carefully ideated multi-dimensional sales strategy. (outlined in detail)
REVENUE
GENERATION
Nexalin Technology is poised to meet its
revenue goals as a result of:
- The rapidly expanding acceptance of telehealth and digital health.
- A newly structured joint venture with an experienced medical technology distribution company in China to design and implement a comprehensive business model and distribution plan for China, Hong Kong, Macau and Taiwan.
- Our carefully ideated multi-dimensional sales strategy. (outlined in detail)